Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Germ”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02459067
What this trial is testing

ImmuniCell® in Patients With Advanced Cancers

Who this might be right for
Malignant MelanomaNon-small Cell Lung CancerRenal Cell Cancer
TC Biopharm 8
Early research (Phase 1)Active Not RecruitingNCT02359565
What this trial is testing

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeLynch SyndromeMalignant Glioma+8 more
National Cancer Institute (NCI) 71
Testing effectiveness (Phase 2)Study completedNCT00453310
What this trial is testing

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Who this might be right for
Extragonadal Germ Cell TumorOvarian CancerTeratoma+1 more
Memorial Sloan Kettering Cancer Center 10
Testing effectiveness (Phase 2)Looking for participantsNCT06640582
What this trial is testing

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Who this might be right for
Brain TumorBrain MetastasesBrain Cancer+4 more
Essen Biotech 85
Testing effectiveness (Phase 2)Study completedNCT00047281
What this trial is testing

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Who this might be right for
Brain and Central Nervous System Tumors
Dana-Farber Cancer Institute
Early research (Phase 1)Study completedNCT02909777
What this trial is testing

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Who this might be right for
LymphomaNeuroblastomaBrain Tumor+1 more
Dana-Farber Cancer Institute 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT03698994
What this trial is testing

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing Sarcoma+33 more
National Cancer Institute (NCI) 20
Not applicableEnded earlyNCT00813501
What this trial is testing

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseInfection+7 more
City of Hope Medical Center 60
Large-scale testing (Phase 3)Study completedNCT00008359
What this trial is testing

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00198159
What this trial is testing

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

Who this might be right for
Refractory Germ Cell Tumors Expressing EGRF
Indiana University 21
Early research (Phase 1)Study completedNCT01425008
What this trial is testing

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Who this might be right for
MelanomaMetastatic MelanomaSolid Tumor+1 more
Millennium Pharmaceuticals, Inc. 149
Testing effectiveness (Phase 2)Study completedNCT00883688
What this trial is testing

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Who this might be right for
Brain CancerPediatric Cancers
M.D. Anderson Cancer Center 24
Early research (Phase 1)Study completedNCT00098761
What this trial is testing

VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

Who this might be right for
Brain and Central Nervous System Tumors
Pediatric Brain Tumor Consortium 42
Testing effectiveness (Phase 2)Ended earlyNCT01032070
What this trial is testing

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Who this might be right for
Recurrent or Refractory Pediatric Ependymoma
OSI Pharmaceuticals 25
Testing effectiveness (Phase 2)Study completedNCT00064311
What this trial is testing

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
National Institutes of Health Clinical Center (CC)
Large-scale testing (Phase 3)Looking for participantsNCT06624644
What this trial is testing

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Who this might be right for
Melanoma (Skin Cancer)Melanoma Stage IIIB-IVCutaneous Melanoma+1 more
Linnaeus Therapeutics, Inc. 135
Large-scale testing (Phase 3)Study completedNCT00690430
What this trial is testing

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Who this might be right for
Symptomatic Refractory Resistant Carcinoid Disease
Novartis Pharmaceuticals 186
Testing effectiveness (Phase 2)Looking for participantsNCT06803875
What this trial is testing

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

Who this might be right for
Relapsed NeuroblastomaRefractory NeuroblastomaHigh-risk Neuroblastoma
Roberto Chiarle 42
Early research (Phase 1)Ended earlyNCT02110563
What this trial is testing

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Who this might be right for
Solid TumorsMultiple MyelomaNon-Hodgkins Lymphoma+3 more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 50
Testing effectiveness (Phase 2)Ended earlyNCT03595683
What this trial is testing

Pembrolizumab and EDP1503 in Advanced Melanoma

Who this might be right for
Melanoma (Skin)Melanoma
University of Chicago 8
Next Page